Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564214 | 1.00 | KMT2A (0.53) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| Ethylene Glycol SCHEMBL3521351 | 0.92 | SLC1A2 (0.47) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL28121172 | 0.92 | KMT2A (0.47) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| Alanine SCHEMBL1421340 | 0.92 | KMT2A (0.47) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL10609538 | 0.86 | KMT2A (0.53) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL18020563 | 0.81 | SLC1A2 (0.45) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL31620921 | 0.80 | SLC1A2 (0.40) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| Ethylene Glycol SCHEMBL9329904 | 0.80 | ALDH1A1 (0.44) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL9182487 | 0.79 | KMT2A (0.49) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B | |
| SCHEMBL542300 | 0.77 | RAB9A (0.41) | KMT2AMEN1SLC1A2CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2075 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689898-B1 | LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| US-20250092336-A1 | PROTEASE VARIANTS AND USES THEREOF | DANISCO US INC (US) | 2025-03-20 | — | — | US | claimed |
| EP-3782653-B1 | COMPOSITION COMPRISING PEGYLATED ARGININE DEIMINASE | POLARIS GROUP (TW) | 2025-03-19 | — | — | EP | claimed |
| CN-119529003-A | Albumin-binding doxorubicin prodrug, self-assembled nanoparticle thereof and application thereof | 沈阳药科大学 | 2025-02-28 | — | — | CN | claimed |
| CN-118027176-B | Human beta 2-microglobulin mutant | 郑春杨 | 2024-12-24 | — | — | CN | claimed |
| EP-3389696-B1 | AMELIORATING SYSTEMIC SCLEROSIS WITH DEATH RECEPTOR AGONISTS | UNIV JOHNS HOPKINS (US) | 2024-11-27 | — | — | EP | claimed |
| US-12146122-B2 | Protease variants and uses thereof | DANISCO US INC. (US) | 2024-11-19 | — | — | US | claimed |
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2024-10-24 | — | — | US | claimed |
| CN-109477112-B | Protease variants and uses thereof | 丹尼斯科美国公司 | 2024-09-06 | — | — | CN | claimed |
| CN-118027176-A | Human beta 2-microglobulin mutant | 郑春杨 | 2024-05-14 | — | — | CN | claimed |
| EP-1171631-B1 | ASSAY FOR DETECTING PHOSPHO-N-ACETYLMURAMYL-PENTAPEPTIDE TRANSLOCASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-10-13 | — | — | EP | claimed |
| EP-0876166-B1 | USE OF INJECTABLE OR IMPLANTABLE BIOMATERIALS FOR FILLING OR BLOCKING LUMENS AND VOIDS OF THE BODY | COHESION TECH INC (US) | 2004-08-18 | — | — | EP | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| WO-2003070805-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030023023-A1 | Hydrolytically degradable polymers and hydrogels made therefrom | SHEARWATER CORPORATION | 2003-01-30 | — | — | US | claimed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | claimed |
| US-6348558-B1 | OLIGOMERS COMPRISING ALKYLENE OXIDE MONOMERS AND CARBONATE LINKAGES; POLYCARBONATEETHER COPOLYMERS; DRUG DELIVERY; CONJUGATED TO PEPTIDES OR PROTEINS FOR REDUCED IMMUNOGENICITY; STABILITY | SHEARWATER CORPORATION | 2002-02-19 | — | — | US | claimed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | claimed |
| CN-1059562-A | Reduce the method for carryover contamination in the amplification procedure | AMGEN INC (US) | 1992-03-18 | — | — | CN | claimed |
| US-4608246-A | Testing for a blood group immunological reaction | IMMUCOR, INC. (US) | 1986-08-26 | — | — | US | claimed |